Recombinant Human IL-17A/F Heterodimer Protein
R&D Systems, part of Bio-Techne | Catalog # 5194-IL
Key Product Details
- R&D Systems E. coli-derived Recombinant Human IL-17A/F Heterodimer Protein (5194-IL)
- Quality control testing to verify active proteins with lot specific assays by in-house scientists
- All R&D Systems proteins are covered with a 100% guarantee
Source
E. coli
Accession #
Structure / Form
Disulfide-linked heterodimer
Conjugate
Unconjugated
Applications
Bioactivity
Product Specifications
Source
E. coli-derived human IL-17A/F Heterodimer protein
| Met | Human IL-17A (Ile20-Ala155) Accession # Q16552 |
|
| Met | Human IL-17F (Arg31-Gln163) Accession # Q96PD4 |
|
| N-terminus | C-terminus |
Purity
>95%, by SDS-PAGE under reducing conditions and visualized by silver stain.
Endotoxin Level
<0.01 EU per 1 μg of the protein by the LAL method.
N-terminal Sequence Analysis
Met (IL-17A) & Met (IL-17F)
Predicted Molecular Mass
IL-17A: 15.7 kDa and IL-17F: 15 kDa
Activity
Measured by its ability to induce IL-6 secretion by NIH-3T3 mouse embryonic fibroblast cells. Yao, Z. et al. (1995) Immunity 3:811.
The ED50 for this effect is 3-15 ng/mL.
The ED50 for this effect is 3-15 ng/mL.
Reviewed Applications
Read 3 reviews rated 4.7 using 5194-IL in the following applications:
Formulation, Preparation and Storage
Carrier Free
What does CF mean?CF stands for Carrier Free (CF). We typically add Bovine Serum Albumin (BSA) as a carrier protein to our recombinant proteins. Adding a carrier protein enhances protein stability, increases shelf-life, and allows the recombinant protein to be stored at a more dilute concentration. The carrier free version does not contain BSA.
What formulation is right for me?In general, we advise purchasing the recombinant protein with BSA for use in cell or tissue culture, or as an ELISA standard. In contrast, the carrier free protein is recommended for applications, in which the presence of BSA could interfere.
Carrier: 5194-IL
| Formulation | Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA with BSA as a carrier protein. |
| Reconstitution | Reconstitute at 100 μg/mL in sterile 4 mM HCl containing at least 0.1% human or bovine serum albumin. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Carrier Free: 5194-IL/CF
| Formulation | Lyophilized from a 0.2 μm filtered solution in Acetonitrile and TFA. |
| Reconstitution | Reconstitute at 100 μg/mL in 4 mM HCI. |
| Shipping | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
|
Background: IL-17A/F Heterodimer
References
- Wright, J.F. et al. (2007) J. Biol. Chem. 282:13447.
- Chang, S.H. and C. Dong (2007) Cell Res. 17:435.
- Kawaguchi, M. et al. (2004) J. Allergy Clin. Immunol. 114:1265.
- Kolls, J.K. and A. Linden (2004) Immunity 21:467.
- Gu, C. et al. (2013) Cytokine 64:477.
- Cheung, P.F.Y. et al. (2008) J. Immunol. 180:5625.
- Liang, S.C. et al. (2007) J. Immunol. 179:7791.
- Ouyang, W. et al. (2008) Immunity 28:454.
- Steinman, L. (2007) Nat. Med. 13:139.
- Hunter, C.A. (2005) Nat. Rev. Immunol. 5:521.
- Kuestner, R.E. et al. (2007) J. Immunol. 179:5462.
- Wright, J.F. et al. (2008) J. Immunol. 181:2799.
- Sarkar, S. et al. (2014) Clin. Exp. Immunol. 177:652.
Long Name
Interleukin 17 A/F
Alternate Names
CTLA8, CTLA8cytotoxic T-lymphocyte-associated serine esterase 8, Cytotoxic T-lymphocyte-associated antigen 8, Cytotoxic T-Lymphocyte-Associated Protein 8, IL17, IL-17, IL-17A, interleukin 17 (cytotoxic T-lymphocyte-associated serine esterase 8), interleukin 17A, interleukin-17A
Additional IL-17A/F Heterodimer Products
Product Documents for Recombinant Human IL-17A/F Heterodimer Protein
Product Specific Notices for Recombinant Human IL-17A/F Heterodimer Protein
For research use only
Loading...
Loading...
Loading...